JP2013531008A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531008A5
JP2013531008A5 JP2013518242A JP2013518242A JP2013531008A5 JP 2013531008 A5 JP2013531008 A5 JP 2013531008A5 JP 2013518242 A JP2013518242 A JP 2013518242A JP 2013518242 A JP2013518242 A JP 2013518242A JP 2013531008 A5 JP2013531008 A5 JP 2013531008A5
Authority
JP
Japan
Prior art keywords
carbon atoms
enantiomer
pharmaceutical composition
composition according
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518242A
Other languages
English (en)
Japanese (ja)
Other versions
JP5921539B2 (ja
JP2013531008A (ja
Filing date
Publication date
Priority claimed from US12/827,529 external-priority patent/US8623913B2/en
Application filed filed Critical
Publication of JP2013531008A publication Critical patent/JP2013531008A/ja
Publication of JP2013531008A5 publication Critical patent/JP2013531008A5/ja
Application granted granted Critical
Publication of JP5921539B2 publication Critical patent/JP5921539B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518242A 2010-06-30 2011-06-27 下肢静止不能症候群を治療する方法 Active JP5921539B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/827,529 US8623913B2 (en) 2010-06-30 2010-06-30 Methods for treating restless legs syndrome
US12/827,529 2010-06-30
PCT/KR2011/004677 WO2012002688A2 (en) 2010-06-30 2011-06-27 Methods of treating restless legs syndrome

Publications (3)

Publication Number Publication Date
JP2013531008A JP2013531008A (ja) 2013-08-01
JP2013531008A5 true JP2013531008A5 (enExample) 2014-08-07
JP5921539B2 JP5921539B2 (ja) 2016-05-24

Family

ID=45400169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518242A Active JP5921539B2 (ja) 2010-06-30 2011-06-27 下肢静止不能症候群を治療する方法

Country Status (8)

Country Link
US (1) US8623913B2 (enExample)
EP (1) EP2588099B1 (enExample)
JP (1) JP5921539B2 (enExample)
KR (1) KR101785072B1 (enExample)
CN (1) CN103025326B (enExample)
CA (1) CA2801243C (enExample)
ES (1) ES2638074T3 (enExample)
WO (1) WO2012002688A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
AU2010270971B2 (en) 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
RU2019114940A (ru) 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
DK3021838T3 (da) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN121202730A (zh) 2016-09-06 2025-12-26 爱尔兰贾兹制药有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的制备方法、其组合物及用途
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
JP7074750B2 (ja) 2016-10-06 2022-05-24 ジャズ ファーマスティカルズ アイルランド リミテッド カルバモイルフェニルアラニノール化合物およびその使用
KR20200016889A (ko) 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
SG11202000817SA (en) 2017-07-31 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol analogs and uses thereof
US11283085B1 (en) 2020-03-06 2022-03-22 Bloom Energy Corporation Low VOC ink compositions and methods of forming fuel cell system components using the same
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11515543B1 (en) 2020-06-03 2022-11-29 Bloom Energy Corporation Aqueous fuel cell system component ink compositions and methods of forming fuel cell system components using the same
CN121620365A (zh) 2023-06-29 2026-03-06 艾克萨姆治疗股份有限公司 向哺乳期妇女施用索安非托的方法
US12201783B1 (en) * 2023-09-05 2025-01-21 Steven F Pichette Use of blue-light filtering eyeglasses for treatment of restless legs syndrome
WO2026125068A1 (en) 2024-12-10 2026-06-18 Noucor Health, S.A. Process to obtain solriamfetol hydrochloride

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CA2240060C (en) 1996-10-10 2007-07-17 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
KR20010043032A (ko) 1998-04-28 2001-05-25 도모따께 다께시 1-[(1-치환-4-피페리디닐)메틸]-4-피페리딘 유도체, 그의제조방법, 그것을 함유하는의약조성물 및 이 화합물의중간체
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
MXPA03007721A (es) 2001-02-27 2004-11-12 Johnson & Johnson Compuesto de carbamato para su uso en el tratamiento del dolor.
RS50676B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
CA2449249A1 (en) 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
US20040115263A1 (en) * 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
WO2004026868A1 (en) 2002-09-20 2004-04-01 Pfizer Japan Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
PL1664036T3 (pl) 2003-09-03 2012-04-30 Pfizer Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
MX2007012463A (es) 2005-04-08 2007-11-07 Pfizer Prod Inc Heteroarilamidas[3.1.0]biciclicas como inhibidores del transporte de glicina de tipo i.
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
PL1890684T3 (pl) * 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
AU2007313017A1 (en) * 2006-10-13 2008-04-24 Janssen Pharmaceutica, N.V. Phenylalkylamino carbamate compositions
US7377267B2 (en) * 2006-10-30 2008-05-27 Ford Global Technologies, Llc Injection strategy to maximize efficiency in gaseous engine
CN101317949A (zh) * 2008-07-15 2008-12-10 洛阳梓生科技开发有限公司 一种补血调经养血柔肝胶囊的制作方法
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
AU2010270971B2 (en) 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue

Similar Documents

Publication Publication Date Title
JP2013533253A5 (enExample)
RU2012155118A (ru) Способы лечения биполярного расстройства
JP2015505296A5 (enExample)
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
PH12012502572A1 (en) Novel nicotinamide derivative or salt thereof
JP2013509392A5 (enExample)
JP2011037901A5 (enExample)
EA201391341A1 (ru) Производные гетероциклических аминов
JP2013536188A5 (enExample)
RU2008100019A (ru) Способ лечения чрезмерной дневной сонливости (варианты)
MY168937A (en) Ethynyl derivatives as modulators of mglur5 receptor activity
JP2014505107A5 (enExample)
RU2013141559A (ru) Способ ингибирования клеток опухоли гамартомы
JP2012521353A5 (enExample)
UA102397C2 (ru) Производные индола как активаторы nurr-1 и их применение для лечения болезни паркинсона
PH12015502692B1 (en) Ethynyl derivatives as metabotropic glutamate receptor antagonists
RU2016111390A (ru) Неконкурентные антагонисты никотиновых рецепторов
JP2010523540A5 (enExample)
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500346A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
JP2011006409A5 (enExample)
NZ714111A (en) Alpha-substituted glycinamide derivative
RU2011137435A (ru) Производные 3-бензофуранилиндол-2-она, замещенные в положении 3, их получение и их применение в терапии
RU2011137408A (ru) Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии
AR059149A1 (es) Derivados de indoloquinoxalina con actividad anti viral